Cellarity’s Post

Exciting news from Flagship Pioneering as they announce the raise of $3.6 billion to fuel breakthrough innovations that transform human health and sustainability. We are proud to be #FlagshipFounded and part of an ecosystem of companies – present and future – taking bold scientific leaps to deliver a better future for all.

Our CEO Fabrice Chouraqui tells Drug Target Review how we’re leveraging #AI to transform #DrugDiscovery and tackle diseases like never before. Read the full article:

We're excited to share that our CEO, Fabrice Chouraqui, was featured in a recent STAT interview! Fabrice discussed how Cellarity is leveraging multi-omics data and artificial intelligence to shift the focus from single molecular targets to the cellular dysfunction underlying diseases. Our new approach has led to the development of candidates for #SickleCellDisease and autoimmune diseases. Discover the future of health care and innovation by reading the full interview:   https://lnkd.in/eB_uatfF  

#SickleCellDisease is a devastating, inherited blood disease that impacts 5M people around the world, leading to excruciating pain crises and other health complications. Our most advanced program is in #SickleCell. We are proud to be part of an ecosystem including organizations like #ThroughThePain and others working tirelessly to advocate for better care, support and research around this disease. Together, we can create #HopeThroughProgress.     Learn more about this disease and our ongoing work to give these patients hope at Cellarity: https://bit.ly/4evHPgc   #WorldSickleCellDay 

Our CEO, Fabrice Chouraqui, recently sat down with Axios to discuss how we’re using the transformative power of #AI and #ML to gain deeper insights into disease biology – so we can revolutionize drug creation.    Read the full interview: https://lnkd.in/ere5xNzD

We are delighted to welcome Christopher Woelk ("Topher") to our team as our new VP and Head of Platform!     Topher brings with him a wealth of expertise in powerful techniques that lead to new target identification and biomarker discovery. As Head of Platform, he will shape the strategy of our end-to-end AI platform to help us unlock a new paradigm of drug creation.    Welcome, Topher!

Last week, we hosted our partners from Novo Nordisk and Pioneering Medicines at our labs in Somerville. In partnership with the world's metabolic health leader, we’re working hard to use our platform to uncover novel insights for people living with Metabolic dysfunction-associated steatohepatitis #MASH. 

Thank you to Labiotech.eu for naming us as one of Boston’s top biotech companies. We love being part of the local, thriving biotech community!